<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7128376/table_3" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 3</label>
  <p>Ongoing clinical trials for COVID–19.</p>
 </caption>
 <thead>
  <tr>
   <th colspan="1" rowspan="1" id="0-0-.">S. no.</th>
   <th colspan="1" rowspan="1" id="0-1-.">Study</th>
   <th colspan="1" rowspan="1" id="0-2-.">Drug</th>
   <th colspan="1" rowspan="1" id="0-3-.">Status</th>
   <th colspan="1" rowspan="1" id="0-4-.">Organization</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td>1.</td>
   <td>Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19</td>
   <td>Sarilumab</td>
   <td>Recruiting</td>
   <td>Regeneron Study Site 
    <br/>New York, New York, United States 
   </td>
  </tr>
  <tr>
   <td>2.</td>
   <td>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</td>
   <td>Remdesivir</td>
   <td>Recruiting</td>
   <td>1. Hoag Memorial Hospital Presbyterian 
    <br/>Newport Beach, California, United States 
    <br/>2.Stanford Hospital, Stanford, California, United States 
    <br/>3. Providence Regional Medical Center Everett, Everett, Washington, United States 
   </td>
  </tr>
  <tr>
   <td>3.</td>
   <td>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</td>
   <td>Remdesivir</td>
   <td>Recruiting</td>
   <td>1. Hoag Memorial Hospital Presbyterian 
    <br/>Newport Beach, California, United States 
    <br/>2.Stanford Hospital, Stanford, California, United States 
    <br/>3. Providence Regional Medical Center Everett, Everett, Washington, United States 
   </td>
  </tr>
  <tr>
   <td>4.</td>
   <td>Fingolimod in COVID-19</td>
   <td>Fingolimod 0.5 mg</td>
   <td>Recruiting</td>
   <td>Wan-Jin Chen 
    <br/>Fuzhou, China 
   </td>
  </tr>
  <tr>
   <td>5.</td>
   <td>The Clinical Study of Carrimycin on Treatment Patients With COVID-19</td>
   <td>1.Carrimycin 
    <br/>2. Lopinavir/ritonavir tablets or Arbidol or Chloroquine phosphate 
   </td>
   <td>Not yet recruiting</td>
   <td>–</td>
  </tr>
  <tr>
   <td>6.</td>
   <td>Efficacy and Safety of Corticosteroids in COVID-19</td>
   <td>Methylprednisolone</td>
   <td>Recruiting</td>
   <td>1. Hubei province hospital of integrated Chinese &amp; Western Medicine 
    <br/>Wuhan, Hubei, China 
    <br/>2. Yichang first people's Hospital 
    <br/>Yichang, Hubei, China 
    <br/>3. Renmin Hospital of Wuhan University 
    <br/>Wuhan, China 
   </td>
  </tr>
  <tr>
   <td>7.</td>
   <td>Mild/Moderate 2019-nCoV Remdesivir RCT</td>
   <td>Remdesivir</td>
   <td>Recruiting</td>
   <td>Jin Yin-tan hospital 
    <br/>Wu Han, Hubei, China 
   </td>
  </tr>
  <tr>
   <td>8.</td>
   <td>Adaptive COVID-19 Treatment Trial</td>
   <td>Remdesivir</td>
   <td>Recruiting</td>
   <td>1.National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section 
    <br/>Bethesda, Maryland, United States 
    <br/>2. University of Nebraska Medical Center - Infectious Diseases 
    <br/>Omaha, Nebraska, United States 
    <br/>3. University of Texas Medical Branch - Division of Infectious Disease 
    <br/>Galveston, Texas, United States 
    <br/>4. Providence Sacred Heart Medical Center 
    <br/>Spokane, Washington, United States 
   </td>
  </tr>
  <tr>
   <td>9.</td>
   <td>Severe 2019-nCoV Remdesivir RCT</td>
   <td>Remdesivir</td>
   <td>Recruiting</td>
   <td>Bin Cao 
    <br/>Beijing, Beijing, China 
   </td>
  </tr>
  <tr>
   <td>10.</td>
   <td>Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.</td>
   <td>Nitric Oxide Gas</td>
   <td>Not yet recruiting</td>
   <td>–</td>
  </tr>
  <tr>
   <td>11.</td>
   <td>Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients</td>
   <td>Recombinant human interferon α1β</td>
   <td>Not yet recruiting</td>
   <td>–</td>
  </tr>
  <tr>
   <td>12.</td>
   <td>Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection</td>
   <td>1.ASC09/ritonavir group 
    <br/>2. Lopinavir/ritonavir group 
   </td>
   <td>Not yet recruiting</td>
   <td>–</td>
  </tr>
  <tr>
   <td>13.</td>
   <td>Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection</td>
   <td>mRNA-1273</td>
   <td>Not yet recruiting</td>
   <td>Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases 
    <br/>Seattle, Washington, United States 
   </td>
  </tr>
  <tr>
   <td>14.</td>
   <td>Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure</td>
   <td>Methylprednisolone</td>
   <td>Recruiting</td>
   <td>Medical ICU,Peking Union Medical College Hospital 
    <br/>Beijing, Beijing, China 
   </td>
  </tr>
  <tr>
   <td>15.</td>
   <td>Lopinavir/Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment</td>
   <td>1. Lopinavir/ritonavir 
    <br/>2. Ribavirin 
    <br/>3. Interferon Beta-1B 
   </td>
   <td>Recruiting</td>
   <td>University of Hong Kong, Queen Mary Hospital 
    <br/>Hong Kong, Hong Kong 
   </td>
  </tr>
  <tr>
   <td>16.</td>
   <td>Efficacy of Chloroquine and Lopinavir/Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study</td>
   <td>1.Chloroquine 
    <br/>2. Lopinavir/Ritonavir 
   </td>
   <td>–</td>
   <td>The Fifth Affiliated Hospital Sun Yat-Sen University</td>
  </tr>
  <tr>
   <td>17.</td>
   <td>A study for the efficacy of hydroxychloroquine for mild and moderate COVID-19 infectious diseases</td>
   <td>Hydroxychloroquine</td>
   <td>–</td>
   <td>The Second Affiliated Hospital of Chongqing Medical University</td>
  </tr>
  <tr>
   <td>18.</td>
   <td>A prospective, randomized, open-label, parallel controlled trial for the preventive effect of hydroxychloroquine on medical personnel after exposure to COVID-19</td>
   <td>Hydroxychloroquine</td>
   <td>–</td>
   <td>Renmin Hospital of Wuhan University</td>
  </tr>
  <tr>
   <td>19.</td>
   <td>The efficacy and safety of carrimycin treatment in patients with novel coronavirus infectious disease (COVID-19): a multicenter, randomized, open- label controlled trial</td>
   <td>Carrimycin</td>
   <td>–</td>
   <td>Beijing You'an Hospital, Capital Medical University</td>
  </tr>
  <tr>
   <td>20.</td>
   <td>A prospective clinical study for recombinant human interferon alpha 1b spray in the prevention of novel coronavirus (COVID-19) infection in highly exposed medical staffs.</td>
   <td>recombinant human interferon alpha 1b</td>
   <td>–</td>
   <td>Chinese PLA General Hospital</td>
  </tr>
  <tr>
   <td>21.</td>
   <td>A Pilot Study of Sildenafil in COVID-19</td>
   <td>Sildenafil citrate</td>
   <td>Recruiting</td>
   <td>Department and Institute of Infectious Disease, Wuhan, Hubei, China</td>
  </tr>
  <tr>
   <td>22.</td>
   <td>Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)</td>
   <td>
    <ul list-type="simple" id="l0005">
     <li class="list-item" id="li0005">
      <p class="label">1.</p>
      <p id="p0005">Lopinavir/ritonavir</p>
     </li>
     <li class="list-item" id="li0010">
      <p class="label">2.</p>
      <p id="p0010">Hydroxychloroquine sulfate</p>
     </li>
    </ul>
   </td>
   <td>Recruiting</td>
   <td>Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of Korea</td>
  </tr>
  <tr>
   <td>23.</td>
   <td>The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19</td>
   <td>Thalidomide</td>
   <td>Not yet recruiting</td>
   <td>–</td>
  </tr>
  <tr>
   <td>24.</td>
   <td>Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID19: A Randomized Control Trial</td>
   <td>Oral</td>
   <td>Not yet recruiting</td>
   <td>Subsai Kongsaengdao, Bangkok, Thailand</td>
  </tr>
  <tr>
   <td>25.</td>
   <td>Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting</td>
   <td>Chloroquine</td>
   <td>Not yet recruiting</td>
   <td>–</td>
  </tr>
  <tr>
   <td>26.</td>
   <td>Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019</td>
   <td>Favipiravir Combined with Tocilizumab</td>
   <td>Recruiting</td>
   <td>Anhui Medical University Affiliated First Hospital, Hefei, Anhui, China 
    <br/>Guiqiang Wang, Beijing, Beijing, China 
    <br/>Peking University First Hospital, Beijing, Beijing, China 
   </td>
  </tr>
  <tr>
   <td>27.</td>
   <td>Trial of Treatments for COVID-19 in Hospitalized Adults</td>
   <td>1.Remdesivir 
    <br/>2.Lopinavir/ritonavir 
    <br/>3. Interferon Beta-1A 
   </td>
   <td>Not yet recruiting</td>
   <td>–</td>
  </tr>
  <tr>
   <td>28.</td>
   <td>Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization</td>
   <td>Losartan</td>
   <td>Not yet recruiting</td>
   <td>Hennepin County Medical Center, Minneapolis, Minnesota, United States 
    <br/>M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States 
    <br/>University of Minnesota, Minneapolis, Minnesota, United States 
   </td>
  </tr>
  <tr>
   <td>29.</td>
   <td>Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization</td>
   <td>Losartan</td>
   <td>Not yet recruiting</td>
   <td>Hennepin County Medical Center, Minneapolis, Minnesota, United States 
    <br/>M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States 
    <br/>University of Minnesota, Minneapolis, Minnesota, United States 
   </td>
  </tr>
  <tr>
   <td>30.</td>
   <td>Evaluation of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of Novel Coronavirus Infection</td>
   <td>Ganovo with ritonavir +/-Interferon</td>
   <td>Recruiting</td>
   <td>The Ninth Hospital of Nanchang 
    <br/>Nanchang, Jiangxi, China 
   </td>
  </tr>
  <tr>
   <td>31.</td>
   <td>Eculizumab (Soliris) in Covid-19 Infected Patients</td>
   <td>Eculizumab</td>
   <td>Initiated</td>
   <td>–</td>
  </tr>
  <tr>
   <td>32.</td>
   <td>Expanded Access Remdesivir (RDV; GS-5734™)</td>
   <td>Remdesivir</td>
   <td>Initiated</td>
   <td>–</td>
  </tr>
  <tr>
   <td>33.</td>
   <td>Norwegian Coronavirus Disease 2019 Study</td>
   <td>Hydroxychloroquine Sulfate</td>
   <td>Not yet recruiting</td>
   <td>–</td>
  </tr>
  <tr>
   <td>34.</td>
   <td>Post-exposure Prophylaxis for SARS-Coronavirus-2</td>
   <td>Hydroxychloroquine</td>
   <td>Recruiting</td>
   <td>University of Minnesota, Minneapolis, Minnesota, United States</td>
  </tr>
  <tr>
   <td>35.</td>
   <td>The efficacy and safety of pirfenidone capsules in the treatment of severe new coronavirus pneumonia (COVID-19)</td>
   <td>Pirfenidone</td>
   <td>–</td>
   <td>Third Xiangya Hospital of Central South University</td>
  </tr>
 </tbody>
 <tfoot>
  <p class="fn" charset="fn">
   <p>The table represents a list of selected clinical trials for the amelioration of COVID–19 specific drugs and vaccines.</p>
  </p>
 </tfoot>
</table>
